Avid Bioservices Inc (CDMO)

[Protector]

geocappy, the CAR-T approvals from KITE (GILD) and others are recent (2017).

GILD's PR related to the approval

GILD Acquired KITE BEFORE the outcome of the clinical trial was known to KITE.

The deal might have been influenced by Novartis and ROCHE that preferred not to have a 3rd competitor with GILD's pocket depth and determination. They can more easily compete with KITE and probably absorb it to consolidate the market and end up with two players in advance on the others in CAR-T. That is comparable to BMY/Merck and their initial advantage on the other anti-PD-1 and anti-CTLA-4 players.

GILD entering CAR-T in this way has by the way EXTRA meaning. We know from history that GILD goes for a market or doesn't. But they don't go in between. If GILD wants to be #1 in CAR-T as they were in there previous market that made them great then they are NOT going to take the risk to let their competitor buy the potential "NON TOXIC UNLOCK" for CAR-T in solid cancers by ROCHE or Novartis.

GILD (KITE) knows that the market of SOLID CANCERS for CAR-T is much much bigger then the one for non-solid cancers.

So PPHM has much more to offer to GILD then KITE did. And besides that IP/Pipelines includes MUCH MORE then just CAR-T applications. The other chemo/radio and IO markets will not be gone overnight. CAR-T does ALSO not work for 100% of the patients. So GILD could license PS-Targeting to anti-PD-1 etc players or Chemo+IO combo players such as ROCHE. Of course Roche has them all and hence PPHM R&D may have more value for them.

And if we are talking acquisition vs buy-out we are ALSO talking biomarkers (the ability to UP-FRONT tell for what patients Bavituximab can successfully be combined in, say, CAR-T combo's). And diagnostics (EXOSOMES liquid biopsy all solid cancers).

So I think PPHM, even with a NON YET APPROVED Sunrise has something more important and that is that data needed to prove to BP that PS-Targeting WORKS and is extremely safe. GILD, Roche or Novartis would only need to run a trial to approve it with the drug they want to combine it with which is very possibly not Docetaxel in CAR-T :)

We should close ranks and make sure that value is leveraged in OUR PPHM shares and if not that we get a detailed explanation why it is worthless with the FULL disclosure of ALL DATA (since it is worthless there is no reason for secrecy) so that everything can put put to scrutiny.

I cannot imagine any LONG LONG could oppose that plan, could they.


AIMO